NFO Alert: HDFC Mutual Fund Launches HDFC Charity Fund for Cancer Cure (Feb 2030)

HDFC Mutual Fund is launching the HDFC Charity Fund for Cancer Cure (Feb 2030), a close-ended debt scheme with a maturity period of 1,169 days. The New Fund Offer (NFO) will remain open from November 16 to November 30, 2026. 

The scheme will invest in debt instruments, money market instruments and government securities that mature on or before the scheme's maturity date.  

Its investment objective is to generate income over the tenure, although there is no assurance that this will be achieved. 

IDCW Donation Options 

The scheme has two Income Distribution cum Capital Withdrawal (IDCW) options. Investors can choose to donate either 50% or 75% of their IDCW to the Indian Cancer Society (ICS).  

The donation will be collected through a one-time mandate after the distribution is made. The remaining IDCW and maturity proceeds will be paid to investors. 

HDFC Asset Management Company (HDFC AMC) will match the donated amount, subject to an annual limit of ₹16 crore. The AMC will not charge investment management or advisory fees.  

A nominal base expense ratio of 3 basis points will apply, while expenses exceeding this amount and distribution costs will be borne or reimbursed by the AMC. 

Minimum Investment and Other Details 

The minimum investment during the New Fund Offer (NFO) is ₹50,000, with additional investments in multiples of ₹1,000. The scheme is available under Direct and Regular plans and has no entry or exit load. 

Anil Bamboli and Gopal Agrawal, for overseas investments, will manage the scheme. It is benchmarked against the NIFTY Medium Duration Debt Index A-III. The scheme carries relatively high interest rate risk and relatively low credit risk. 

Previous Cancer Cure Fund Contributions 

HDFC AMC and its four earlier cancer cure funds contributed ₹292.41 crore to ICS between 2011 and September 2026. As of August 31, 2026, 17,435 patients had received treatment assistance, with ₹273.28 crore disbursed. 

The programme covers surgery, chemotherapy, radiation therapy and supportive care. Eligible patients must be Indian citizens with annual family income of up to ₹4 lakh. Assistance is capped at ₹5 lakh per patient, rising to ₹8 lakh for bone marrow transplants. 

Read More: Global Gold Prices Drop 6.87% in October 2026, Indian Gold ETFs Deliver Up to 7.54% YTD Returns! 

Conclusion  

The scheme combines investments in debt instruments with donations to the Indian Cancer Society. Investors can choose the donation percentage, while the remaining IDCW and maturity proceeds will be paid to them. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Mutual Fund Investments are subject to market risks, read all the related documents carefully before investing.